Open AccessImpact of the Data Collection on Adverse Events of Anti-HIV Drugs Cohort Study on Abacavir Prescription among Treatment-Naive, HIV-Infected Patients in Canada
Author(s) -
Tony Antoniou,
Jennifer Gillis,
Mona Loutfy,
Curtis Cooper,
Robert S. Hogg,
Marina B. Klein,
Nimâ Machouf,
Julio S. G. Montaner,
Sean B. Rourke,
Chris Tsoukas,
Janet Raboud
Publication year - 2013
Publication title -
journal of the international association of providers of aids care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.813
H-Index - 31
eISSN - 2325-9582
pISSN - 2325-9574
DOI - 10.1177/2325957413495565
Subject(s) - medicine , abacavir , odds ratio , medical prescription , confidence interval , cohort , cohort study , adverse effect , retrospective cohort study , human immunodeficiency virus (hiv) , pediatrics , viral load , antiretroviral therapy , family medicine , pharmacology
Objective: To evaluate the trends in abacavir (ABC) prescription among antiretroviral (ARV) medication-naive individuals following the presentation of the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) cohort study.Methods: We conducted a retrospective cohort study of ARV medication-naive individuals in the Canadian Observational Cohort (CANOC).Results: Between January 1, 2000, and February 28, 2010, a total of 7280 ARV medication-naive patients were included in CANOC. We observed a significant change in the proportion of new ABC prescriptions immediately following the release of DAD (−11%; 95% confidence interval [CI]: −20% to −2.4%) and in the months following the presentation of these data (−0.66% per month; 95% CI: −1.2% to −0.073%). A post-DAD presentation decrease in the odds of being prescribed ABC versus tenofovir (TDF) was observed (adjusted odds ratio, 0.72 per year, 95% CI: 0.54-0.97).Conclusions: Presentation of the DAD was associated with a significant decrease in ABC use among ARV medication-naive, HIV-positive patients initiating therapy.